COVID-19 in teriflunomide-treated patients with multiple sclerosis

Amir Hadi Maghzi, Maria K. Houtchens, Paolo Preziosa, Carolina Ionete, Biljana D. Beretich, James M. Stankiewicz, Shahamat Tauhid, Ann Cabot, Idanis Berriosmorales, Tamara H.W. Schwartz, Jacob A. Sloane, Mark S. Freedman, Massimo Filippi, Howard L. Weiner, Rohit Bakshi

Research output: Contribution to journalArticlepeer-review


The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.

Original languageEnglish
Pages (from-to)2790-2796
Number of pages7
JournalJournal of Neurology
Issue number10
Publication statusPublished - Oct 1 2020


  • Antiviral
  • Coronavirus
  • COVID-19
  • Multiple sclerosis
  • Teriflunomide

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'COVID-19 in teriflunomide-treated patients with multiple sclerosis'. Together they form a unique fingerprint.

Cite this